<DOC>
	<DOCNO>NCT00063791</DOCNO>
	<brief_summary>The purpose study give patient 4 prior line therapy multiple myeloma access VELCADE . The study patient eligible clinical trial VELCADE VELCADE would otherwise available .</brief_summary>
	<brief_title>A Study Assess Two Different Strategies Combining Dexamethasone VELCADE</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Major Criteria : Plasmacytomas tissue biopsy Bone marrow plasmacytosis ( &gt; 30 % plasma cell ) Monoclonal IgG &gt; 3.5 g/dL IgA &gt; 2.0 g/dL ; kappa lambda light chain excretion &gt; 1 g/day 24 hour urine sample . Minor criterion : Bone marrow plasmacytosis ( 10 30 % ) Monoclonal immunoglobulin present less magnitude give major criterion . Lytic bone lesions Other Eligibility Requirements : Patient eligible Millennium Study M34101039 . Patient receive 4 line therapy multiple myeloma , investigator 's opinion , currently need therapy relapse progressive disease . Patient legal consenting age , define local regulation . Patient , investigator 's opinion , willing able comply protocol requirement . Patient give voluntary write informed consent performance studyrelated procedure part normal medical care . Female patient must either postmenopausal , surgically sterilize , willing use acceptable method birth control throughout study . Male patient must agree use acceptable method birth control throughout study . Patient Karnofsky performance status great equal 60 % . Patient meet pretreatment laboratory criterion within 14 21 day Baseline ( Day 1 Cycle 1 , study drug administration ) . Patient progress receive VELCADE previously clinical trial . Patient treat Millennium Study M34101039 . Patient receive corticosteroid ( &gt; 10 mg/day prednisone equivalent ) within 1 week enrollment study . Patient receive nitrosoureas within 6 week chemotherapy within 3 week enrollment study . Patient receive immunotherapy antibody therapy within 4 week enrollment . Patient major surgery 4 week enrollment ( kyphoplasty n't consider major surgery ) . Patient history allergic reaction due compound contain boron mannitol . Patient peripheral neuropathy Grade 2 great , define National Cancer Institute Common Toxicity Criteria ( NCI CTC ) . Patient myocardial infarction within 6 month enrollment New York Heart Association ( NYHA ) class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia electrocardiogram show evidence acute ischemia active conduction system abnormality . Patient cardiac amyloidosis Patient poorly control hypertension , diabetes mellitus , serious medical psychiatric illness could potentially interfere completion treatment . Patient know infected human immunodeficiency virus ( HIV positive ) . Patient know hepatitis B positive active hepatitis C infection . Patient active systemic infection require treatment . Female patient pregnant breastfeeding . Confirmation patient pregnant require . Pregnancy test require postmenopausal surgically sterilize patient .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2003</verification_date>
	<keyword>Relapsed Refractory</keyword>
</DOC>